Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Iovance Biotherapeutics Inc

Current price
6.4 USD -0.27 USD (-4.05%)
Last closed 6.38 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 602 046 720 USD
Yield for 12 month -7.51 %
21.11.2021 - 28.11.2021

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. Address: 825 Industrial Road, San Carlos, CA, United States, 94070


WallStreet Target Price

20.42 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

+469 000 USD

Last Quarter

+238 000 USD

Current Year

Last Year

Current Quarter

-3 871 000 USD

Last Quarter

-1 812 000 USD

Key Figures IOVA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -434 616 992 USD
Operating Margin TTM -25236.89 %
PE Ratio
Return On Assets TTM -39.9 %
PEG Ratio
Return On Equity TTM -81.1 %
Wall Street Target Price 20.42 USD
Revenue TTM 707 000 USD
Book Value 2.64 USD
Revenue Per Share TTM 0.003 USD
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -2.08 USD
Diluted Eps TTM -2.08 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics IOVA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IOVA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:100
Payout Ratio
Last Split Date 26.09.2013
Dividend Date

Stock Valuation IOVA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1867.2638
Price Sales TTM 2265.9783
Enterprise Value EBITDA -3.1642
Price Book MRQ 2.3769

Financials IOVA

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators IOVA

For 52 weeks

3.21 USD 9.36 USD
50 Day MA 4.35 USD
Shares Short Prior Month 38 861 574
200 Day MA 6.26 USD
Short Ratio 6.04
Shares Short 35 593 714
Short Percent 15.13 %